Headergrafik - Weinfest

Guest lecture by Simon Salzman from Boehringer Ingelheim at EBS

24 February 2021 | By: Prof. Dr. Markus Kreutzer, Professor of Strategic and International Management
Guest Lecture Simon Salzmann

“How did COVID-19 impact M&A in the pharma industry?” We invited Simon Salzman, Senior Manager M&A at Boehringer Ingelheim to our MSc course on “Managing Mergers and Acquisitions”.

After working in corporate finance and investment banking at Accuracy and Lincoln International Simon “switched sides” and now leads M&A deals at Boehringer Ingelheim.

In his talk, Simon shared valuable insights into current M&A dynamics in the pharma industry:

  • While the COVID-19 crisis is often compared to the credit crunch in 2007/2008, markets have quickly recovered and a surge in strategic deal activity can be observed.
  • The existing liquidity in the market continues to finance rising biotech firms, which outperform classical pharma companies’ performance.
  • Under these circumstances, pharma incumbents need to navigate corporate development modes diligently: Early ties to aspiring biotech firms can lead to valuable advantages in the bidding process.
  • The acquisition process does not stop after the deal transaction: To leverage the biotech firms’ unique intellectual property, post-merger integration strategies already need to be crafted while assessing the target company.

To the Newsroom of EBS Universität

Markus Kreutzer Portrait quer

Professor of Strategic and International Management

Group Speaker Management

+49 611 7102 1413